Management of patients with advanced non-small cell lung cancer: role of gefitinib.

Biologics · 2010 · PMC2880342 · PMID 20531966

Europe PMC DOI

hedged sentence

0.0890

closest p · 1.8× alpha

0.0890

boldest claim

The sentences

did not reach statistical significanceP = 0.089so close (0.05 < p ≤ 0.1)

Similarly, despite numerically superior median survival (6.3 months versus 5.4 months) and 1-year survival (30% versus 18%), the benefit from gefitinib did not reach statistical significance compared to best supportive care in patients with adenocarcinoma (HR 0.84; 95% CI 0.68–1.03; P = 0.089).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.